

Haili Qian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7493103/publications.pdf>

Version: 2024-02-01

35
papers

922
citations

516710

16
h-index

477307

29
g-index

36
all docs

36
docs citations

36
times ranked

1264
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances. <i>Leukemia</i> , 2021, 35, 312-332.	7.2	151
2	Enriched CD44+/CD24 ^{low} population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). <i>Cancer Letters</i> , 2014, 353, 153-159.	7.2	113
3	ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. <i>Oncotarget</i> , 2016, 7, 66020-66031.	1.8	75
4	A TGF- β -MTA1-SOX4-EZH2 signaling axis drives epithelial \rightarrow mesenchymal transition in tumor metastasis. <i>Oncogene</i> , 2020, 39, 2125-2139.	5.9	69
5	Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. <i>International Journal of Cancer</i> , 2020, 146, 1359-1368.	5.1	55
6	Reduced MTA1 Expression by RNAi Inhibits In Vitro Invasion and Migration of Esophageal Squamous Cell Carcinoma Cell Line. <i>Clinical and Experimental Metastasis</i> , 2005, 22, 653-662.	3.3	48
7	The subcellular distribution and function of MTA1 in cancer differentiation. <i>Oncotarget</i> , 2014, 5, 5153-5164.	1.8	37
8	RNA interference of metastasis-associated gene 1 inhibits metastasis of B16F10 melanoma cells in a C57BL/6 mouse model. <i>Biology of the Cell</i> , 2007, 99, 573-581.	2.0	36
9	Subcellular localization of MTA proteins in normal and cancer cells. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 843-856.	5.9	36
10	Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 59.	5.2	32
11	Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. <i>BMC Cancer</i> , 2019, 19, 442.	2.6	26
12	Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis. <i>Scientific Reports</i> , 2017, 7, 5995.	3.3	25
13	CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT. <i>European Journal of Cancer</i> , 2021, 145, 92-108.	2.8	24
14	The emerging role of RNA N6-methyladenosine methylation in breast cancer. <i>Biomarker Research</i> , 2021, 9, 39.	6.8	22
15	MTA1 regulates higher-order chromatin structure and histone H1 \rightarrow chromatin interaction in vivo. <i>Molecular Oncology</i> , 2015, 9, 218-235.	4.6	20
16	Chromatin modifier MTA1 regulates mitotic transition and tumorigenesis by orchestrating mitotic mRNA processing. <i>Nature Communications</i> , 2020, 11, 4455.	12.8	20
17	The molecular tumor burden index as a response evaluation criterion in breast cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 251.	17.1	19
18	The Clinical Characteristics of Endometrial Cancer With Extrapertoneal Metastasis and the Value of Surgery in Treatment. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382094578.	1.9	13

#	ARTICLE	IF	CITATIONS
19	Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer. Biomarker Research, 2021, 9, 28.	6.8	13
20	Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers. Breast, 2020, 52, 17-22.	2.2	12
21	MTA1 promotes tumorigenesis and development of esophageal squamous cell carcinoma via activating the MEK/ERK/p90RSK signaling pathway. Carcinogenesis, 2020, 41, 1263-1272.	2.8	11
22	Metastasis-associated gene 1 promotes invasion and migration potential of laryngeal squamous cell carcinoma cells. Oncology Letters, 2014, 7, 399-404.	1.8	10
23	The characteristics of isolated para-aortic lymph node metastases in endometrial cancer and their prognostic significance. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093303.	3.2	9
24	Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer. Frontiers in Oncology, 2021, 11, 602222.	2.8	9
25	Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells. Biomedicine and Pharmacotherapy, 2018, 99, 608-614.	5.6	8
26	Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER2-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients. Cancer Medicine, 2022, , .	2.8	8
27	The clinical characteristics and prognosis of endometrial carcinomas that occur after breast cancer: does hormone receptor status of breast cancer matter?. Archives of Gynecology and Obstetrics, 2019, 300, 1399-1404.	1.7	5
28	Cancer metastasis-associated protein 1 localizes to the nucleolus and regulates pre-rRNA synthesis in cancer cells. Journal of Cellular Biochemistry, 2021, 122, 180-188.	2.6	4
29	Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers.. Journal of Clinical Oncology, 2018, 36, 1039-1039.	1.6	4
30	Upregulation of MTA1 in Colon Cancer Drives A CD8+ T Cell-Rich But Classical Macrophage-Lacking Immunosuppressive Tumor Microenvironment. Frontiers in Oncology, 2022, 12, 825783.	2.8	4
31	Comprehensive analysis reveals GRP94 is associated with worse prognosis of breast cancer. Translational Cancer Research, 2021, 10, 298-309.	1.0	2
32	MTA1: A Vital Modulator in Prostate Cancer. Current Protein and Peptide Science, 2022, 23, 456-464.	1.4	2
33	The therapy and mechanisms of replication-deficient recombinant adenovirus Ad-p14ARF in hepatocellular carcinoma. Chinese-German Journal of Clinical Oncology, 2007, 6, 22-26.	0.1	0
34	Landscape of somatic mutations in different subtypes: Advanced breast cancer with circulating tumour DNA analysis.. Journal of Clinical Oncology, 2017, 35, e23039-e23039.	1.6	0
35	The role of RARRES2 in regulating lipid metabolic reprogramming in the development of brain metastases in triple negative breast cancer.. Journal of Clinical Oncology, 2022, 40, e13047-e13047.	1.6	0